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Abstract: The progression of HIV disease has been markedly slowed by the use of highly active antiretroviral therapy 
(HAART). However, substantial genetic variation was observed to occur among different people in the decay rate of viral 
loads caused by HAART. The characterization of specific genes involved in HIV dynamics is central to design personal-
ized drugs for the prevention of this disease, but usually cannot be addressed by experimental methods alone rather than 
require the help of mathematical and statistical methods. A novel statistical model has been recently developed to detect 
genetic variants that are responsible for the shape of HAART-induced viral decay curves. This model was employed to an 
HIV/AIDS trial, which led to the identification of a major genetic determinant that triggers an effect on HIV dynamics. 
This detected major genetic determinant also affects several clinically important parameters, such as half-lives of infected 
cells and HIV eradication times.  
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1. INTRODUCTION 
  A current hope for avoiding the fatal consequences of 
HIV-1 infection lies in treatments with highly active antiret-
roviral therapy (HAART), which consists of combinations of 
three or more drugs that inhibit HIV reverse transcriptase or 
protease [1]. When patients are treated with HAART, the 
load of virions (plasma HIV-1 RNA copies) detectable in 
their blood plasma usually drops sharply. Although consid-
erable variation has been observed in the dynamics of the 
change of viral load among patients [2-4], little is known 
about the control mechanisms of genes in regulating viral 
decay with time. 
  The change of viral loads with time is a dynamic process, 
whose genetic control may also follow a temporal pattern. 
The genetic mapping of a dynamic trait has proven to be 
very difficult due to its high-dimensionality, but a key issue 
related to dynamic mapping has been resolved at the Univer-
sity of Florida by proposing a statistical model, called func-
tional mapping [5]. Functional mapping integrates the 
mathematical equations of a biological process into a general 
genetic mapping framework in which the tests for genetic 
control are based on curve parameters that specify the dy-
namic pattern. In this article, we extend the idea of func-
tional mapping to detect a major genetic determinant predis-
posing to the decline of viral load after initiation of HAART 
by incorporating the mathematical analysis of HIV dynam-
ics. We further show how the genetic determinant detected is 
activated to affect HIV dynamics and how it controls clini-
cally important variables in AIDS/HIV trials.  
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2. METHODS  
  In general, the amount of virions after initiation of treat-
ment with potent antiretroviral agents follows a certain dy-
namic pattern that can be characterized by mathematical 
functions. Based on a firm understanding of biological inter-
actions using real virological data from clinical trials, some 
simplified forms of HIV dynamic models have been derived 
[6]. Fig. (1) illustrates the dynamics of viral load for 53 HIV-
1-infected patients after the treatment with HAART from the 
AIDS Clinical Trials Group (ACTG) Protocol 315, sup-
ported by the National Institute of Allergy and Infectious 
Diseases. Viral loads of these patients were measured on 
days 0, 2, 7, 10, 14, 21, 28 and weeks 8 and 12. This ACTG 
315 dataset is of typical longitudinal nature and has been 
subjected to extensive statistical analyses [6, 7]. In particu-
lar, Wu and Ding [6] have shown that HIV-1 dynamics for 
the ACTG 315 data can be adequately fitted by a bi-
exponential function, expressed as  
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where  and  1 and 2 represent the initial viral production 
rates in two different biological compartments, productively 
infected cells and long-lived and/or latently infected cells, 
and  d1 and d2 are the decay rates of these two compartments, 
respectively. Different combinations of the curve parameters 
(1, 2, d1, d2) determine the shapes of the dynamic change 
of HIV-1 after the treatment with HAART.  
  Whether or not there exists a major genetic determinant 
to control HIV-1dynamics or curves in hosts can be tested by 
using a functional mapping model proposed to map a longi-
tudinal trait [5, 8]. The hypothesis tests embedded within the  
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functional mapping context allow for the exploration of the 
control mechanism of agenetic determinant in regulating the 
time-dependent curve changes of HIV-1 load. The statistical 
foundation of functional mapping is based on the mixture 
model in which each curve fitted by a series of measure-
ments at   time points for any subject, arrayed by y  =  
[y(1),…,  y()], is assumed to have arisen from one of a 
known or unknown number of components, each component 
being modeled by a multivariate normal distribution density. 
Assuming that there are L  genotypes contributing to the 
variation among different curves, this mixture model is ex-
pressed as  
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are the mixture proportions (i.e., 
genotype frequencies) which are constrained to be non-
negative and sum to unity;  T
1 ) , , ( L    … =
 
are the compo-
nent-(or genotype) specific parameters, with 1 being spe-
cific to component l; and  is parameters which are common 
to all components. The likelihood function of longitudinal 
data measured for a random sample of size n is constructed 
as  
, )] , ; ( ) , ; ( [ ) | , , (
1
1 1 
=
+ + =
n
i
L i L i f f L          y y y    (3)  
where all samples are assumed to have independent re-
sponses to times. Traditional mapping methods [9] can be 
readily extended to accommodate the multivariate nature of 
time-dependent traits. The multivariate normal distribution 
of individual i  measured at  time points is expressed as  
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where  )] ( , ), 1 ( [  i i i y y … = y  is a vector of observation meas-
ured at   time points and  )] ( , ), 1 ( [  μ μ l l l … = m  is a vector 
of expected values for genotype l at different points. At a 
particular time t, the relationship between the observation 
and expected mean can be described by a linear regression 
model, 
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where  il x  is the indicator variable denoted as 1 if a genotype 
l is considered for subject  i and 0 otherwise;  ) (t ei  is the 
residual error that is iid normal with the mean of zero and the 
variance of  ) (
2 t  . The errors at two different time points, t1 
and t2, are correlated with the covariance of cov(t1, t2). These 
(co)variances comprise a (    ) matrix  . 
The use of a traditional multivariate mapping approach to 
map genes for a longitudinal trait is limited in three aspects: 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Load trajectories of HIV-1 virions (measured in viral RNA copies) for 53 patients (with shadow curves) during the first 12 weeks 
after the initiation of HAART for the ACTG 315 data. HIV dynamics can be adequately fitted by a biexponential equation. The three thick 
curves each represent a different genotype (denoted by AA, Aa or aa) at a major genetic determinant detected by the functional mapping ap-
proach and can better explain the data than a single population mean curve (LR = 31.42 > critical threshold of 24.67 at   = 0.01 estimated 
from 1000 simulation replicates). The curves of the three genotypes are described by V2(t) = e
11.6959-0.3677t + e
6.6988+0.0584t for genotype AA, 
V1(t) = e
11.9814-0.2726t + e
8.2763+0.0202t for genotype Aa, and V0(t) = e
10.6641-0.3477t + e
6.8662-0.0303t for genotype aa. Note that the two homozygotes 
can be arbitrarily assigned by AA or aa in this example because no marker information is provided. The hypothesis tests for the genotypic 
differences of d1 and d2 suggest that the major gene detected affects the turnovers of HIV in two different virus compartments.  210    Current Genomics, 2008, Vol. 9, No. 3  Ma et al. 
(1) individual expected means of different genotypes at all 
points and all elements in the matrix   need to be estimated, 
resulting in substantial computational difficulties when the 
vector and matrix dimension is large; (2) the result from this 
approach may not be biologically meaningful because the 
underlying biological principle for the longitudinal trait is 
not incorporated; and (3) this approach cannot be well de-
ployed on a practical scheme because of (2). Thus, some 
biologically interesting questions cannot be asked and an-
swered.  
  The functional mapping model includes two tasks: (1) 
model the time-dependent expected means of genotype l 
using a mathematical function, such as Equation 1 for HIV-
1dynamics; and (2) model the structure of the within-subject 
(co)variance matrix using the autoregressive [AR(1)] model, 
expressed as  
2 2 2 ) ( ) 1 (     = = =   
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for the covariance between any two time intervals t1 and t2, 
where  1 0 < <   is the proportion parameter with which the 
correlation decays with time lag. The incorporation of these 
tasks into the likelihood function leads to the significant re-
duction of the parameter number. With this incorporation, 
we will estimate the curve parameters and matrix parameters 
arrayed by  ) , , , , , (
2
2 1 2 1     d d  rather than individual geno-
typic means at different time points for HIV-1 progression 
mapping.  
  We also need to derive a procedure for estimating the 
genotype frequencies () for the HIV-1 dynamics genetic 
determinant in a sample of patients drawn from a natural 
population. For a mapping project, these genotype frequen-
cies can be expressed as the conditional probabilities of the 
genotypes of interest conditional upon the known marker 
genotypes. But for the ACTG 315 data in which marker 
genotypes have not been collected yet, we can only test 
whether there is a latent segregating major gene for HIV-1 
dynamics. Suppose there is a major genetic determinant with 
two alleles A and a that affects HIV-1 dynamics. Let q and  
1 - q denote the allele frequencies for A and a, respectively. 
The three genotypes at the major gene, AA, Aa and aa, have 
genotypic frequencies expressed as  D q + =
2
1  , 
D q q 2 ) 1 ( 2 2   =  , and  D q +  =
2
3 ) 1 (  , respectively, 
where D is the coefficient of Hardy-Weinberg disequilibrium 
at the major gene. For an arbitrarily chosen patient, he or she 
must carry one (and only one) of the three genotypes, with a 
probability represented by 1, 2 or 3. The mixture model 
for all individuals based on these three latent genotypes es-
tablishes a theoretical foundation for characterizing an indi-
vidual’s major genotype. More recently, we have derived a 
closed-form solution for the EM algorithm to estimate the 
genotypic frequencies of a major genetic determinant in a 
population [10].  
3. RESULTS AND DISCUSSION  
  By incorporating the bi-exponential function of HIV-1 
dynamics into the EM-implemented mapping framework, we 
have successfully detected a putative host major genetic de-
terminant responsible for HIV dynamics in the ACTG data. 
The log-likelihood ratio (LR) test statistic (31.42) for the full 
model (there is a major gene) over the reduced model (there 
is no major gene) was calculated, and it is much greater than 
the critical threshold (24.67, P=0.0001) determined from 
simulated data under the null hypothesis that there is no ma-
jor gene. However, it is possible that the three classifications 
of viral load response curves identified from our model may 
also be due to other treatment factors, like ages and sex. A 
mixed model incorporating these factors is proposed from 
which the evidence for the existence of a major genetic de-
terminant is observed. The three genotypes at the detected 
major genetic determinant displayed marked differentiations 
in their viral load trajectories (Fig. 1). The heterozygote (Aa) 
and one homozygote (denoted by aa) that together account 
for an overwhelming majority of patients (~90%) were found 
to decline consistently with time in viral load after initiation 
of antiretroviral drugs. For the second homozygote (AA) in 
the frequency of ~10%, viral load turns out to increase from 
day 20 following a short period of decline after the drug ad-
ministration. We estimated allele frequencies for the major 
genetic determinant detected, which are 0.32 for the allele 
causing the increase of viral load after day 20 and 0.68 for 
the allele maintaining a consistent decline. No significant 
Hardy-Weinberg disequilibrium (D) was detected according 
to the log-likelihood ratio test.  
  The two decay rates of different virus compartments, d1 
and d2, have clinical values in AIDS trials [7]. The half-lives 
of productively infected cells (
1 2 / 1 / 2 log d t = ) were esti-
mated as (1.9, 2.5, 2.0) days for three major genotypes AA, 
Aa and aa, respectively. The corresponding 
2 / 1 t  values of 
long-lived and/or latently infected cells (
2 / 2 log d ) were es-
timated as (11.9, 34.4, 22.9) days. While the major genetic 
determinant detected has a nonsignificant effect on the half-
life of productively infected cells (LRd
1 =3.29, d.f. = 2, P > 
0.05), it triggers a significant effect on the half-life of long-
lived and/or latently infected cells (LRd
2 = 10.30, d.f. = 2, P < 
0.01). The control of the detected major genetic determinant 
over the half-times of long-lived and/or latently infected 
cells suggests a possibility of altering second-phase viral 
load trajectories through a gene therapy strategy.  
  We calculated the eradication times for the two com-
partments, productively infected cells and long-lived and/or 
latently infected cells, approximated by 
1 1 1 / log d   =   and 
2 2 2 / log d   = , respectively [7]. The estimated eradication 
times for the three QTL genotypes are (6.7, 9.1, 6.8) days for 
the first virus compartment and (32.6, 104.8, 63.6) days for 
the second virus compartment. We found that the major ge-
netic determinant detected displayed significant effects on 
the eradication times for the two compartments (LR
1 =6.84, Modeling the Genetic Control of HIV-1 Dynamics  Current Genomics, 2008, Vol. 9, No. 3    211 
d.f. = 2, P < 0.05 and LR
2 = 13.19, d.f. = 2, P < 0.01). The 
genetic regulation of eradication times may assist clinicians 
in optimizing drug therapy on the basis of each patient’s ge-
netic constitution.  
  Due to the staggering number of people infected with 
HIV (40 million), it is important to develop the most potent 
drugs to quickly eliminate all HIV from the blood and from 
the body. The detection of a major genetic determinant for 
HIV dynamics strongly suggests that HIV infection can be 
more efficiently prevented and curbed only after personal-
ized strategies of gene therapy have been designed based on 
the gene a particular patient carries. The genetic determina-
tion of the life spans of infected cells during different phases 
implies that the virus may be fully eradicated through the 
development of individualized therapy.  
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